

# Helicobacter pylori Infection is a Significant Factor Risk for Hyperhomocysteinemia in the Patients with Coronary Artery Disease

Soudabeh Fallah<sup>1\*</sup>, Nariman Moradi<sup>2</sup>, Fadaei Reza<sup>2</sup>, Ahmadi Reza<sup>2</sup>, Tabatabaei Azardokht<sup>2</sup>, Morteza Seifi<sup>3</sup>

<sup>1</sup>Hemmat Highy way, Iran (the Islamic Republic of); <sup>2</sup>Iran University of Medical Sciences – Biochemistry, Tehran, Iran (the Islamic Republic of); <sup>3</sup>University of Alberta - Medical Genetics, Edmonton, Canada

## ABSTRACT

*This work aimed to determine whether seropositivity to Helicobacter pylori infection was an independent risk factor for hyperhomocysteinemia patients with cardiovascular disease. The H. pylori IgG, IgA and homocystein levels in 96 patients with cardiovascular disease and 64 participants free of cardiovascular disease as control subjects were determined by ELISA assay. The results showed that seropositivity to H. pylori IgG and IgA levels of coronary artery disease (CAD) patients was significantly higher than the controls and CAD patients with H. pylori IgG and IgA negative antibodies. A significant correlation was found between the seropositivity to H. pylori IgG and homocysteine levels of CAD patients in comparison with the controls and CAD patients with seronegativity to H. pylori IgG and IgA ( $r=0.233$ ,  $P= 0.019$ ). The involvement of H. pylori infection in atherosclerosis process was based on the chronic inflammation, which might facilitate the CAD-related pathologies. The effect of the presence of H. pylori infection on homocysteine levels elevation in the CAD patients (as a risk factor independent of other traditional factors) was remarkable.*

**Key words:** Cardiovascular disease, ELISA assay, homocysteine, *Helicobacter pylori*

---

\* Author for correspondence: fallah.s@iums.ac.ir

## INTRODUCTION

Cardiovascular disease is the most common cause of mortality and morbidity in the United States and many other nations (Reddy-Vanga et al. 2010). Coronary atherosclerosis process is multi-factorial. Traditional and classic cardiovascular risk factors such as diabetes mellitus (DM), hypertension (HTN), smoking and obesity have introduced as major causes, but significant proportions of the patients with coronary artery disease (CAD) do not have these traditional risks. Other factors, which may affect this chronic process, have been evaluated (Folsom et al. 1998; Reddy-Vanga et al. 2010; Rogha et al. 2012). For example, infection-related chronic inflammation from *Helicobacter pylori* (*H. pylori*) is one of the CAD risk factors, because the CAD risk factors plasma fibrinogen, C-reactive protein, and blood leukocyte count become elevated in the seropositive subjects (Folsom et al. 1998). *H. pylori* infection is the most common infection worldwide, especially in the developing countries (Rogha et al. 2012). According to many reports, 70-90% of apparently healthy people of developing countries are estimated to be infected with *H. pylori* (Rogha et al. 2012; Chmiela et al. 2015; Javadi et al. 2015). *H. pylori* is a Gram-negative bacterium with perfect adaptation to the acidic environment of the stomach and high affinity to gastric epithelial cells. Recently, possible association between *H. pylori* infection and extragastric disorders has been also suggested (Franceschi et al. 2006; Pacifico et al. 2010; Pacifico et al. 2014). An indirect association between the prevalence of *H. pylori* and the occurrence of CAD is demonstrated by many research studies (Rogha et al. 2012; Chmiela et al. 2015; Javadi et al. 2015). A significant association of *H. pylori* infection with CAD (OR 3.18, 95% CI 1.08-9.40) was shown by a multivariate logistic regression analysis (Rogha et al. 2012). According to majority of findings, the involvement of *H. pylori* in this process was based on the chronic inflammation, which might facilitate the CAD-related pathologies (Rogha et al. 2012; Chmiela et al. 2015). Several mechanisms have been proposed for how *H. pylori* might accelerate macrovascular complications and increase CAD risk (Cenerelli et al. 2002; Rogha et al. 2012; Javadi et al. 2015). It has been demonstrated that *H. pylori* is an important and serious cause of elevated levels of homocysteine

(HCY) and is prevalent in the Caucasian population, ranging from 30 to 40% incidence. On the other hand, HCY is recognized as an independent risk factor for cardiovascular diseases. HCY has been demonstrated to be toxic to the endothelial cells and lipoproteins due to generation of oxygen radicals. High level of HCY appears to be one of the factors responsible for the increased risk of vascular damage and clinical CAD events (Sacco et al. 2004). A study on 116 patients with CAD who were matched with 116 controls via age and sex although showed a minor association between *H. pylori* infection and CAD. However, a stronger correlation between higher levels of triglycerides (fats) and lower levels of high density lipoprotein (HDL) - cholesterol was found in the *H. pylori*-infected patients (Laurila et al. 1999; Ekesbo et al. 2000; Hoffmeister et al. 2001; Kowalski 2001). Based on the above findings, these results could be consistent with the hypothesis that *H. pylori* infection might modify the serum lipid concentrations in a way that could increase the risk of CAD (Sacco et al. 2004). Hence, knowing the inflammation as a cardiovascular risk factor in the one hand and *H. pylori* and hyperhomocysteinemia involvement in CAD incidence on the other hand could be interesting to evaluate the *H. pylori* infection effect on HCY levels and atherosclerosis processes.

Thus, this study examined whether *H. pylori* seropositivity was associated with hyperhomocysteinemia and cardiovascular disease occurrence.

## MATERIAL AND METHODS

### Sampling and Coronary Angiography

This study was approved by the Ethical Committee of Iran University of Medical Sciences. The cross-sectional study was performed in Rasool Akram Hospital of Tehran from June 2014 to October 2014. Ninety six consecutive CAD patients (68 men and 28 women; mean age  $52.95 \pm 1.25$  and  $51.32 \pm 1.61$  years old, respectively) and 64 controls were enrolled into the study and candidates for coronary angiography and informed consent were selected. Before catheterization, all the subjects completed a semi-structured questionnaire regarding their past medical and drug history. The diagnosis was based on the decision of an experienced clinician. Coronary

angiography was carried out by left-heart catheterization and arteriography using Judkins method, and then a cardiologist separately reviewed the angiography films. According to angiography reports, the clinical and laboratory evaluated patients with  $\geq 50\%$  coronary stenosis were considered as CAD positive group and participants with  $< 50\%$  coronary stenosis were considered as CAD negative group, or controls. Accordingly, patients with hepatic dysfunction, autoimmune disease, thyroid dysfunction and/or adrenal dysfunction as well as patients who consumed any kinds of glucocorticoids were excluded from the study.

### Biochemical Measurements

Fasting blood sample of catheterization participants were taken to measure lipid profiles, immunoglobulins G and A (anti *H. pylori* IgG and IgA) and homocysteine levels. ELISA kit (Diagnostic kit, PISHTAZ TEB Company, Teheran, Iran) was used to measure the homocysteine levels. Anti-*H. pylori* antibody status was determined by measuring the IgG and IgA antibody by ELISA assay (Diagnostic kit, PISHTAZ TEB Company). Spectrophotometric assay was used for lipid profiles assay.

### Statistical Data Analysis

Statistical analyses were carried out using SPSS software (version 16.0, Chicago, IL, USA). Unpaired student t-tests and ANOVA test were used for comparing the continuous variable. Chi-square test was used for discrete variables. To

compare the association of *H. pylori* infection with homocysteine and thereby CAD, logistic regression tests were used by adjusting the sex and age plus history of diabetes, dyslipidemia, and/or hypertension.

## RESULTS

Demographic characteristics of four study groups are shown in Tables 1 and 2. No significant differences were found in terms of demographic characteristics between the CAD patients and controls with anti-*H. pylori* IgG positive and negative and between the CAD patients and controls with anti-*H. pylori* IgA positive and negative. As shown in Table 1, the anti-*H. pylori* IgG ( $72.49 \pm 3.64$  U/mL) and IgA ( $46.72 \pm 3.24$  U/mL) levels of CAD patient with positive anti-*H. pylori* IgG were significantly more than those were found in the CAD patients with negative anti-*H. pylori* IgG ( $9.34 \pm 2.11$  and  $12.20 \pm 1.15$  U/mL). The values of  $8.05 \pm 0.40$  and  $15.48 \pm 3.18$  U/mL were achieved for anti-*H. pylori* IgG and anti-*H. pylori* IgA of controls with negative anti-*H. pylori* IgG, respectively, which were lower significantly than those found for CAD patient with positive and negative anti-*H. pylori* IgG. The anti-*H. pylori* IgG ( $67.21 \pm 4.00$  U/mL) and anti-*H. pylori* IgA ( $38.90 \pm 3.68$  U/mL) levels of the control group with positive anti-*H. pylori* IgG were lower than CAD patient with positive anti-*H. pylori* IgG but significantly higher than negative anti-*H. pylori* IgG CAD patients.

**Table 1** - Demographic characteristics of CAD patients and controls with positive and negative anti-*H. pylori* IgG

			Control- Negative anti- H.P IgG) N=21	Control- positive anti-H.P IgG) N=43	CAD- Negative anti-H.P IgG N=17	CAD - Positive anti-H.P IgG N=79	P value
Gender	Male		13	19	9	59	0.008
	Female		8	24	8	20	
Smoking	Yes		6	7	6	24	0.309
	No		15	36	11	55	
Diabetes History	Yes		1	4	4	9	0.306
	No		20	39	13	70	
Drinking status	Yes		5	4	5	20	0.307
	No		16	39	12	59	
History of hypertension	Yes		3	6	6	12	0.305
	No		18	37	11	67	
Medication Aspirin	Yes		14	34	15	69	0.129
	No		7	9	2	10	

Statin	Yes	8	18	13	59	<0.001
	No	13	25	4	20	
Lozartan	Yes	5	7	5	21	0.577
	No	16	36	12	58	
Anti H.P IgG( U/mL)		8.05 ± 0.40	67.21 ± 4.00	9.34 ± 2.11	72.49 ± 3.64	<0.001
Anti H.P IgA (U/mL)		15.48 ± 3.18	38.90 ± 3.68	12.20 ± 1.15	46.72 ± 3.24	<0.001
LDL-C ( mg/dL)		105.16 ± 6.84	93.97 ± 3.87	99.27 ± 5.41	98.37 ± 3.08	0.507
HDL-C( mg/dL)		39.53 ± 2.60	38.06 ± 2.06	35.07 ± 1.64	36.96 ± 0.93	0.550
Cholesterol ( mg/dL)		189.26 ± 11.28	167.58 ± 6.37	168.80 ± 7.85	169.12 ± 4.27	0.199
TG ( mg/dL)		152.89 ± 22.46	142.25 ± 16.29	174.07 ± 23.64	126.53 ± 7.19	0.154
FBS( mg/dL)		102.40 ± 4.96	103.21 ± 6.84	106.26 ± 6.60	104.08 ± 2.53	0.983
Age(years)		57.76 ± 2.36	55.49 ± 1.65	56.35 ± 2.47	59.79 ± 1.23	0.187
SBP(mmHg)		126.55 ± 2.61	131.79 ± 2.98	132.40 ± 1.82	131.04 ± 15.70	0.652
DBP(mmHg)		78.35 ± 2.19	80.02 ± 1.91	81.27 ± 2.48	83.15 ± 1.56	0.366
BMI (Kg/m <sup>2</sup> )		27.42 ± 0.74	27.58 ± 0.46	27.58 ± 0.96	26.41 ± 0.27	0.224

Anti H.P, anti-*Helicobacter pylori*; BMI, body mass index; FBS, fast blood sugar; HDL, high-density lipoprotein; LDL-C, low-density lipoprotein; SBP, systolic blood pressure; TG, triglyceride; DBP=diastolic blood pressure. Values are means±sd

According to Table 2,  $64.96 \pm 2.97$  and  $43.63 \pm 3.07$  U/mL of anti-*H. pylori* IgG and anti-*H. pylori* IgA, respectively of CAD patient with positive *H. pylori* IgA were significantly higher than those found for the CAD patients with negative anti-*H. pylori* IgA ( $21.16 \pm 11.20$  and  $7.40 \pm 0.48$  U/mL). Controls with the negative anti-*H. pylori* IgA ( $15.62 \pm 5.31$  and  $6.61 \pm 0.63$  U/mL) and the control subjects with positive anti-*H. pylori* IgA ( $56.81 \pm 4.72$  and  $38.06 \pm 3.24$  U/mL) respectively. As shown in Table 3 and Figure 1 (A), the serum homocysteine concentration of the CAD patients with positive anti-*H. pylori* IgG ( $27.70 \pm 1.28$   $\mu\text{mol/L}$ ) was significantly ( $P=0.05$ ) higher than CAD patients with negative anti-*H. pylori* IgG ( $22.16 \pm 2.19$   $\mu\text{mol/L}$ ). The difference between the HCY levels of CAD patients with positive anti-*H. pylori* IgG ( $27.70 \pm 1.28$   $\mu\text{mol/L}$ ) and the control group with positive anti-*H. pylori* IgG ( $22.38 \pm 1.19$   $\mu\text{mol/L}$ ) was significant ( $P=0.02$ ). The homocysteine levels of the CAD patients with positive anti-*H. pylori* IgG ( $27.70 \pm 1.28$   $\mu\text{mol/L}$ ) was significantly ( $P=0.02$ )

higher than the control subjects with negative anti-*H. pylori* IgG positive ( $20.62 \pm 1.51$   $\mu\text{mol/L}$ ). The serum homocysteine concentration of the control subjects with negative anti-*H. pylori* IgG positive ( $22.38 \pm 1.19$   $\mu\text{mol/L}$ ) and control group with negative anti-*H. pylori* IgG ( $20.62 \pm 1.51$   $\mu\text{mol/L}$ ) was not different significantly ( $P=0.936$ ). A significant correlation with  $r=0.233$ ,  $P=0.019$  was identified between anti-*H. pylori* IgG and homocysteine levels of the CAD patients with positive anti-*H. pylori* IgG (Fig.1 B), while the correlation between the anti-*H. pylori* IgG and homocysteine levels of CAD patients with negative anti-*H. pylori* IgG was not significant ( $r=0.005$ ,  $P=0.493$ ). The correlation between the anti-*H. pylori* IgG and homocysteine levels of the control group with positive and negative anti-*H. pylori* IgG was not significant ( $r=-0.071$ ,  $P=0.325$  and  $r=-0.071$ ,  $P=0.325$ , respectively). It is worth to note that correlation between the anti-*H. pylori* IgG and homocysteine levels of all the subjects was significant ( $r=0.233$ ,  $P=0.002$ ).

**Table 2 - Demographic characteristics of CAD patients and controls with positive and negative *H. pylori* anti IgA**


		Control-Negative anti-H.P IgA N=14	Control-Positive anti-H.P IgA N=50	CAD-Negative anti-H.P IgA N=8	CAD-Positive anti-H.P IgA N=88	P value
Gender	Male	7	25	6	62	0.067
	Female	7	25	2	26	
Smoking	Yes	4	9	3	27	0.372
	No	10	41	5	61	
Diabetes History	Yes	1	4	2	11	0.490

Medication	Aspirin	No	13	46	6	77	0.089
		Yes	9	39	6	78	
	Statin	No	5	11	2	10	<0.001
		Yes	5	21	6	66	
	Lozartan	No	9	29	2	22	0.458
		Yes	4	8	2	24	
		No	10	42	6	64	
Anti H.P IgG( U/mL)			15.62 ± 5.31	56.81 ± 4.72	21.16 ± 11.20	64.96 ± 2.97	<0.001
Anti H.P IgA( U/mL)			6.81 ± 0.63	38.06 ± 3.24	7.40 ± 0.48	43.63 ± 3.07	<0.001
LDL-C( mg/dL)			100.25 ± 7.79	97.24 ± 3.98	107.25 ± 9.10	97.67 ± 92.02	0.768
HDL-C( mg/dL)			39.42 ± 2.40	38.33 ± 1.96	39.75 ± 3.25	36.36 ± 0.85	0.501
Cholesterol( mg/dL)			178.77 ± 9.79	173.93 ± 7.02	176.88 ± 11.61	168.33 ± 4.00	0.728
TG( mg/dL)			165.85 ± 28.64	139.76 ± 14.73	192.50 ± 35.53	128.71 ± 6.68	0.099
FBS( mg/dL)			99.07 ± 6.27	104.08 ± 6.05	112.62 ± 8.99	103.72 ± 2.53	0.817
Age(years)			57.79 ± 3.10	55.80 ± 1.50	59.12 ± 2.99	59.18 ± 1.19	0.370
SBP(mmHg)			128.36 ± 3.06	130.60 ± 2.71	134.43 ± 4.46	131.00 ± 1.78	0.882
DBP( mmHg)			78.64 ± 2.71	79.73 ± 1.74	81.29 ± 3.10	82.96 ± 1.46	0.418
BMI(kg/m <sup>2</sup> )			27.99 ± 0.79	27.53 ± 0.44	26.65 ± 1.51	26.61 ± 0.37	0.306

Anti H.P, anti-helicobacter pylori; BMI, body mass index; FBS, fast blood sugar; HDL, high-density lipoprotein; LDL-C, low-density lipoprotein; SBP= systolic blood pressure; TG, triglyceride; DBP=diastolic blood pressure. Values are means±sd

As shown in Table 4 and Figure 2 A, there was not a significant (P=1) difference between the homocysteine levels of the CAD patients with positive anti-*H. pylori* IgA (24.70 ± 0.80 µmol/L) as comparison with the CAD patients with negative anti-*H. pylori* IgA (26.50 ± 4.49 µmol/L). Serum homocysteine concentration of the CAD patients with positive anti-*H. pylori* IgA (24.70 ± 0.80 µmol/L) was not significantly (P=0.1) higher than the control subjects with positive anti-*H. pylori* IgA (22.79 ± 1.12 µmol/L) but was higher than the controls with negative anti-H.P. IgA positive (17.85 ± 1.07 µmol/L) significantly (P=0.01). The difference between the

homocysteine levels of the control subjects with positive anti-H.P IgA (22.79 ± 1.12 µmol /L) and controls with negative anti *H. pylori* IgA (17.85 ± 1.07 µmol/L) was not different significantly (P=0.34). Serum homocysteine concentration of the CAD patients with negative anti-*H. pylori* IgA (26.50 ± 4.49 µmol/L) was not significantly (P=0.75) higher than the control subjects with positive anti-*H. pylori* IgA (26.50 ± 4.49 µmol /L). A significant correlation (P<0.001, r=0.691) was found between the anti- *H. pylori* IgA and anti *H. pylori* IgG of CAD patients in comparison with non-CAD patients (Fig. 3).



**Figure 1- (A):** Homocysteine levels of CAD patients with positive and negative anti *H. pylori* IgG and controls with positive and negative anti *H. pylori* IgG **(B):** The correlation between homocysteine levels and anti *H. pylori* IgG

levels of CAD patients with positive and negative anti *H. pylori* IgG and of controls with positive and negative anti *H. pylori* IgG groups were identified.

- A) 4 P=0.020 (in comparison with 1); 4 P=0.020 (in comparison with 2); 4, P=0.05 (in comparison with 3); 3, P=1.000 (in comparison with 2); 2, P=0.936 (in comparison with 1); 3, P=0.935 (in comparison with 1); Correlation in all subjects,  $r=0.233$ ,  $P=0.002$ ; ○) Correlation in controls with negative anti *H. pylori* IgG,  $r=0.324$ ,  $P=0.076$ ; □) Correlation in controls with positive anti *H. pylori* IgG,  $r=-0.071$ ,  $P=0.325$ ; ♦) Correlation in CAD patients with negative anti *H. pylori* IgG,  $r=0.005$ ,  $P=0.493$ ; ♦♦) Correlation in CAD patients with positive anti *H. pylori* IgG,  $r=0.233$ ,  $P=0.019$ .

**Table 3** - Homocysteine and anti *H. pylori* IgG and IgA levels of CAD patients with positive and negative anti-H.P IgG

		Control (Negative anti- H.P IgG) n=21	Control (Positive anti-H.P IgG) n=43	CAD (Negative anti-H.P IgG ) N=17	CAD (Positive anti- H.P IgG) N=79	P value
Gender	Male	13	19	9	59	0.008
	Female	8	24	8	20	
Smoking	Yes	6	7	6	24	0.309
	No	15	36	11	55	
Diabetes History	Yes	1	4	4	9	0.306
	No	20	39	13	70	
Medication Aspirin	Yes	14	34	15	69	0.129
	No	7	9	2	10	
Statin	Yes	8	18	13	59	<0.001
	No	13	25	4	20	
Lozartan	Yes	5	7	5	21	0.577
	No	16	36	12	58	
Homocysteine( $\mu\text{mol/L}$ )		20.62 $\pm$ 1.51	22.38 $\pm$ 1.19	22.16 $\pm$ 2.19	27.70 $\pm$ 1.28	0.003
Anti H.P IgG ( U/mL )		8.05 $\pm$ 0.40	67.21 $\pm$ 4.00	9.34 $\pm$ 2.11	72.49 $\pm$ 3.64	<0.001
Anti H.P IgA ( U/mL )		15.48 $\pm$ 3.18	38.90 $\pm$ 3.68	12.20 $\pm$ 1.15	46.72 $\pm$ 3.24	<0.001


Anti H.P, anti *Helicobacter pylori*; Values are means  $\pm$  sd

**Table 4** - Homocysteine and anti *H. pylori* IgG and IgA levels of CAD patients with positive and negative anti *H. pylori* IgA and the control subjects with positive and negative anti-H. Pylori IgA

		Controls- Negative H.P IgA N=14	Controls- positive anti- H.P IgA N=50	CADs- Negative anti- H.P IgA N=8	CADs- Positive anti- H.P IgA N=88	P value
Gender	Male	7	25	6	62	0.067
	Female	7	25	2	26	
Smoking	Yes	4	9	3	27	0.372
	No	10	41	5	61	
Diabetes History	Yes	1	4	2	11	0.490
	No	13	46	6	77	
Medication Aspirin	Yes	9	39	6	78	0.089
	No	5	11	2	10	
Statin	Yes	5	21	6	66	<0.001
	No	9	29	2	22	
Lozartan	Yes	4	8	2	24	0.458
	No	10	42	6	64	
Homocysteine ( $\mu\text{mol/L}$ )		17.85 $\pm$ 1.07	22.79 $\pm$ 1.12	26.50 $\pm$ 4.49	24.70 $\pm$ 0.80	0.007
Anti H.P IgG (U/ml)		15.62 $\pm$ 5.31	56.81 $\pm$ 1.12	21.16 $\pm$ 11.20	64.96 $\pm$ 0.80	<0.001


Anti H.P IgA(U/ml)	6.81 ± 0.63	4.72 38.06 ± 7.40 ± 0.48 3.24	2.97 43.63 ± <0.001 3.07
--------------------	-------------	-------------------------------------	--------------------------------

Values are means±sd



**Figure 2- (A):** Homocysteine levels of the CAD patients with positive and negative anti-*H. pylori* IgA and controls with positive and negative anti-*H. pylori* IgA. **(B):** The correlation between the homocysteine and anti-*H. pylori* IgA levels of CAD patients with positive and negative anti-*H. pylori* and of the controls with positive and negative anti *H. pylori* IgA groups.

A) 4 P=0.011(in comparison with 1); 4 P=0.114(in comparison with 2); 4, P=1.000 (in comparison with 3); 3, P=0.197(in comparison with 1); 2, P=0.346 (in comparison with 1); 2, P=0.754(in comparison with 3); B) Correlation between all groups, r= 0.197, P=0.006; ○) Correlation for controls with negative anti *H. pylori* IgA, r= 0.324, P= 0.076; □) Correlation for controls with positive anti H. pylori IgA, r= -0.081, P=0.335; ♦) Correlation for CAD patients with negative anti H. pylori IgA, r= 0.007, P=0.489; ♦♦) Correlation for CAD patients with positive anti H. pylori IgA, r= 0.075, P=0.256.



**Figure 3-** Correlation between anti-*H. pylori* IgG and anti-*H. pylori* IgA of patients with the controls. r= 0.691, p< 0.001.

## DISCUSSION

Several studies have demonstrated that hyperhomocysteinemia and *H. pylori* infection have contributed in the cardiovascular disease pathogenesis, independent of other conventional risk factors (Sung and Sanderson 1996; Leung et al. 2001; Sharma and Aggarwal 2015). As shown in Tables 1 and 2, there was not a significant difference between the demographic characterization of the patients with CAD and controls. According to Figures 1 A and 2 A, a significant difference was found between anti-H.P. IgG and IgA levels of the patients with CAD (P=0.020) and controls (P=0.011). Serum homocysteine concentration of the patients with CAD was more than the controls significantly. A positive correlation was found between the homocysteine levels and anti-*H. pylori* IgG in the patients with CAD as comparison to the control subjects. It has been proposed that *H. pylori* infection might modify the serum homocysteine concentration in a way that could increase the risk of CAD. The results of a case-control study showed that *H. pylori* infection increased a two-fold risk of CAD (Sung and Sanderson 1996). However, the possible mechanism of a chronic infection by *H. pylori* leading to atherosclerosis is yet to be identified. One of the proposed mechanisms is that *H. pylori* chronic infection increases the acute inflammation factors such as fibrinogen and sialic acid, which are predictors of CAD (Ringnér et al. 1994). In consistent with these results, a higher concentration of fibrinogen and total leukocyte count were reported for the patients with cardiovascular disease and infected by *H. pylori* as comparison to controls (Patel et al. 1995). The other hypothesis is that chronic *H. pylori* infection leads to malabsorption of vitamin B-6, vitamin B-12 and folate, methylation defeat and hyperhomocysteinaemia, thereby inducing arterial damage. It has been shown that nitric oxide secretion from the endothelial cells is inhibited by homocysteine, which comforts platelet aggregation and vasoconstriction. The balance between the procoagulants and anticoagulants might be changed by homocysteine via selective manners such as inhibition of the thrombomodulin processing and releasing, decreasing the protein C activation and inducing a protease activator of coagulation factor V (Sung and Sanderson 1996). Other mechanisms of *H. pylori* infection that could

lead to atherosclerosis are destructive influence of *H. pylori* and its products like cytokines and cytotoxins on coronary endothelium, activation of immune mechanisms, which react with the nuclei of monocytes in atherosclerotic vessel wall and cytoplasm of fibroblast-like cell in atherosclerosis plaques (Rogha et al. 2012). In agreement with the present results, the results of a study on 93 patients under diagnostic coronary arteriography with infection *H. pylori*, showed a significant decrease of vitamin B12 and folate levels, thereby increasing homocysteine levels. They suggested that homocysteine could induce endothelial damage directly, affect platelet function and coagulation factors and increase the oxidation of LDL-C, which have critical role in cardiovascular disease occurrence (Ringnér et al. 1994). In a study patients with *H. pylori* infection exhibited a decreased secretion of ascorbic acid by gastric mucosa and elevated gastric pH, thereby the folate absorption from the diet was decreased due to low ascorbic acid in gastric juice, and subsequently a significant rise was found in homocysteine levels (Lucock et al. 1995). However, it is important to consider that confounding variables such as vitamin deficiency, acute-phase response to vascular diseases, medication use, hypertension, advanced age and gender are well-known factors influencing homocysteinemia and should be considered. An inverse relationship was demonstrated among the homocysteine levels and *H. pylori* infection in the patients with functional dyspepsia in a cross-sectional study by Rasool et al. (2012). The authors showed that 46.2% of *H. pylori*-positive patients had hyperhomocysteinemia (>15 µmol/L) when compared to *H. pylori*-negative group (44%). They also reported that this was a higher proportion in comparison with that was observed in healthy population (Rasool et al. 2012). The results demonstrated that *H. pylori* did affect directly HCY metabolism in the liver (Cenerelli et al. 2002; Longo-Mbenza et al. 2012). They showed that disrupted metabolism of HCY, which was induced by *H. pylori* led to an increase of HCY levels similar to those found in diabetic patients. Emphasizing the probable impairment of insulin function regarding the regulation of HCY level through the homocysteine/methionine metabolism, which caused higher levels of HCY in the CAD patients infected by *H. pylori* and the importance of *H. pylori* infection in determining the elevated HCY levels.



In summary, a small sample size was investigated and these observations should be confirmed in a larger sample of the patients with more analysis works. Here, only two independent variables were analysed, but it would be worthwhile to consider other probable variables involving in CAD disease in future studies.

## CONCLUSION

The present study demonstrated an inverse relationship between the homocysteine levels and *H. pylori* seropositivity (IgG and IgA) and atherosclerosis occurrence in the patients with CAD. Since classic risk factors were not able to explain all cases of CAD, the results of present study suggested that chronic *H. pylori* infection affected the development or maintenance of CAD, since it induced chronic long term infection within gastric epithelium, which led to not only local but systemic inflammation. According to the present findings, the involvement of *H. pylori* in this process was based on the chronic inflammation, which might facilitate the CAD-related pathologies. Moreover, impact of the presence of *H. pylori* was found on homocysteine levels in such patients.

## ACKNOWLEDGEMENTS

This study was supported by a grant from the University of Medical Sciences. The authors would like to thank Rasool Akram Hospital for providing the samples.

## REFERENCES

- Cenerelli S, Bonazzi P, Galeazzi R, Testa I, Bonfigli AR, Sirolla C, et al. *Helicobacter pylori* masks differences in homocysteine plasma levels between controls and type 2 diabetic patients. *Eur J Clin Invest.* 2002; 32(3): 158-62.
- Chmiela M, Gajewski A, Rudnicka K. *Helicobacter pylori* vs coronary heart disease - searching for connections. *World J Cardiol.* 2015; 7(4): 187-203.
- Ekesbo R, Nilsson PM, Lindholm LH, Persson K, Wadström T. Combined seropositivity for *H. pylori* and *C. pneumoniae* is associated with age, obesity and social factors. *J Cardiovasc Risk.* 2000; 7(3): 191-195.
- Folsom AR, Nieto FJ, Sorlie P, Chambless LE, Graham DY. *Helicobacter pylori* seropositivity and coronary heart disease incidence. *Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation.* 1998; 98(9): 845-850.
- Franceschi F, Roccarina D, Gasbarrini A. Extragastric manifestations of *Helicobacter pylori* infection. *Minerva Med.* 2006; 97(1): 39-45.
- Hoffmeister A, Rothenbacher D, Bode G, Persson K, März W, Nauck MA, et al. Current infection with *Helicobacter pylori*, but not seropositivity to *Chlamydia pneumoniae* or cytomegalovirus, is associated with an atherogenic, modified lipid profile. *Arterioscler Thromb Vasc Biol.* 2001; 21(3): 427-32.
- Javadi L, Pourghassem Gargari B, Salekzamani S, Yousefzadeh R. Folate and homocysteine levels and their association with dietary intakes in Iranian patients infected with *Helicobacter pylori*: a case-control study. *Acta Med Iran.* 2015; 53(3): 162-167.
- Kowalski M. *Helicobacter pylori* (H. pylori) infection in coronary artery disease: influence of *H. pylori* eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of *H. pylori* specific DNA in human coronary atherosclerotic plaque. *J Physiol Pharmacol.* 2001; 52(1 Suppl 1): 3-31.
- Laurila A, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. Association of *Helicobacter pylori* infection with elevated serum lipids. *Atherosclerosis.* 1999; 142(1): 207-210.
- Leung WK, Ma PK, Choi PC, Ching JY, Ng AC, Poon P, et al. Correlation between *Helicobacter pylori* infection, gastric inflammation and serum homocysteine concentration. *Helicobacter.* 2001; 6(2): 146-150.
- Longo-Mbenza B, Nsenga JN, Mokondjimobe E, Gombet T, Assori IN, Ibara JR, et al. *Helicobacter pylori* infection is identified as a cardiovascular risk factor in Central Africans. *Vasc Health Risk Manag.* 2012; 6: 455-461
- Lucock MD, Priestnall M, Daskalakis I, Schorah CJ, Wild J, Levene MI. Nonenzymatic degradation and salvage of dietary folate: physicochemical factors likely to influence bioavailability. *Biochem Mol Med.* 1995; 55(1): 43-53.
- Pacifico L, Anania C, Osborn JF, Ferraro F, Chiesa C. Consequences of *Helicobacter pylori* infection in children. *World J Gastroenterol.* 2010; 16(41): 5181-5194.
- Pacifico L, Osborn JF, Tromba V, Romaggioli S, Bascetta S, Chiesa C. *Helicobacter pylori* infection and extragastric disorders in children: a critical update. *World J Gastroenterol.* 2014; 20(6): 1379-1401.
- Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, et al. Association of *Helicobacter pylori* and *Chlamydia pneumoniae* infections with coronary heart disease and cardiovascular risk factors. *BMJ.* 1995; 311(7007): 711-714.

- Rasool S, Abid S, Iqbal MP, Mehboobali N, Haider G, Jafri W. Relationship between vitamin B12, folate and homocysteine levels and *H. pylori* infection in patients with functional dyspepsia: A cross-section study. *BMC Res Notes*. 2012; 5: 206.
- Reddy Vanga S, Good M, Howard PA, Vacek JL. Role of Vitamin D in Cardiovascular Health. *Am J Cardiol*. 2010; 106(6): 798-805.
- Ringnér M, Valkonen KH, Wadström T. Binding of vitronectin and plasminogen to *Helicobacter pylori*. *FEMS Immunol Med Microbiol*. 1994; 9(1): 29-34.
- Rogha M, Nikvarz M, Pourmoghaddas Z, Shirneshan K, Dadkhah D, Pourmoghaddas M. Is helicobacter pylori infection a risk factor for coronary heart disease? *ARYA Atheroscler*. 2012; 8(1): 5-8.
- Sacco RL, Anand K, Lee HS, Boden-Albala B, Stabler S, Allen R, et al. Homocysteine and the risk of ischemic stroke in a triethnic cohort: the Northern Manhattan Study. *Stroke*. 2004; 35(10): 2263-2269.
- Sharma V, Aggarwal A. *Helicobacter pylori*: Does it add to risk of coronary artery disease. *World J Cardiol*. 2015; 7(1): 19-25.
- Sung JJ, Sanderson JE. Hyperhomocysteinaemia, *Helicobacter pylori*, and coronary heart disease. *Heart*. 1996; 76(4): 305-307.

Received:25-Aug-2015

Accepted: 04 Oct-2015